The Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and features dormant and discontinued products.
GlobalData tracks 30 drugs in development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) by 26 companies/universities/institutes. The top development phase for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) is preclinical with seven drugs in that stage. The Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline has 29 drugs in development by companies and one by universities/ institutes. Some of the companies in the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline products market are: Shilpa Biologicals, Swedish Orphan Biovitrum and Generium.
The key targets in the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline products market include Tumor Necrosis Factor, Tyrosine Protein Kinase JAK1, and Interleukin 1 Beta.
The key mechanisms of action in the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline product include Tumor Necrosis Factor Inhibitor with seven drugs in Pre-Registration. The Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline products include nine routes of administration with the top ROA being Subcutaneous and six key molecule types in the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline products market including Monoclonal Antibody, and Small Molecule.
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) overview
Systemic-onset juvenile idiopathic arthritis (Still’s disease) is a rare and serious form of arthritis that affects children. It causes inflammation not only in the joints, but also in other organs such as the liver, heart, and lungs. It is also known as systemic juvenile rheumatoid arthritis or juvenile-onset Still’s disease. The main symptoms of this condition are high fever, rash, and arthritis. The fever usually occurs daily or twice a day, and the rash is salmon-pink and migrates to different parts of the body. Arthritis may develop later in the course of the disease and affect both large and small joints. Other symptoms may include enlargement of the liver, spleen, or lymph nodes; anemia; and inflammation of the lining of the chest or abdomen. The cause of this condition is unknown, but it may be related to genetic, environmental, and hormonal factors. It is diagnosed by excluding other possible causes of fever and arthritis, and by testing for blood markers of inflammation. Treatment options include glucocorticoids, methotrexate, anakinra, and tocilizumab. These drugs can help reduce inflammation and prevent complications such as growth problems, joint damage, or organ failure.
For a complete picture of Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
